Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026)
Sarepta Therapeutics' (SRPT) quarterly Return on Capital Employed came in at 1.48% in Q1 2026, up 229.0% year-on-year from 0.45% in Q1 2025, and up 95.08% quarter-over-quarter from 30.08% in Q4 2025.
Sarepta Therapeutics (SRPT) Return on Capital Employed (2011 - 2026) Analysis & Trends
Sarepta Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 1.48% for Q1 2026.
- On a quarterly basis, Return on Capital Employed rose 229.0% year-over-year to 1.48% in Q1 2026; TTM through Mar 2026 was 1.48%, a 229.0% increase from a year earlier, with the FY2025 full-year figure at 27.32%, down 3489.0% from the prior year.
- Return on Capital Employed rose to 1.48% in Q1 2026 per SRPT's latest filing, from 30.08% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 7.15% in Q4 2024 and bottomed at 30.08% in Q4 2025.
- The 5-year median for Return on Capital Employed is 10.57% (2023), against an average of 10.35%.
- Across the five-year window, Return on Capital Employed surged 2109 bps in 2024 and sank 3723 bps in 2025, its largest moves.
- Year by year, Return on Capital Employed stood at 21.26% in 2022, then jumped by 50 bps to 10.57% in 2023, then surged by 168 bps to 7.15% in 2024, then plunged by 521 bps to 30.08% in 2025, then jumped by 95 bps to 1.48% in 2026.
- Per Business Quant, the three latest SRPT Return on Capital Employed figures stand at 1.48% (Q1 2026), 30.08% (Q4 2025), and 4.75% (Q3 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -31.80% |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -107.40% |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 10.46% |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 21.10% |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 10.19% |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -68.84% |
| 10 | Sarepta Therapeutics | 1.66 Bn | 1.25 Bn | 622.04 Mn | -1.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -1.48% |
| Dec 31, 2025 | -30.08% |
| Sep 30, 2025 | -4.75% |
| Jun 30, 2025 | -0.04% |
| Mar 31, 2025 | -3.77% |
| Dec 31, 2024 | 7.15% |
| Sep 30, 2024 | 2.88% |
| Jun 30, 2024 | 1.44% |
| Mar 31, 2024 | -3.60% |
| Dec 31, 2023 | -10.57% |
| Sep 30, 2023 | -14.97% |
| Jun 30, 2023 | -19.65% |
| Mar 31, 2023 | -22.97% |
| Dec 31, 2022 | -21.26% |
| Sep 30, 2022 | -21.64% |
| Jun 30, 2022 | -17.67% |
| Mar 31, 2022 | -14.91% |
| Dec 31, 2021 | -18.75% |
| Sep 30, 2021 | -22.45% |
| Jun 30, 2021 | -26.84% |